M. Farag Et Al. , "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B," International Liver Congress (ILC) , vol.68, Paris, France, 2018
Farag, M. Et Al. 2018. HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B. International Liver Congress (ILC) , (Paris, France).
Farag, M., Campenhout, M. V., van Boemmel, F., Rijckborst, V., Cakaloglu, Y., Ferenci, P., ... Tabak, F.(2018). HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B . International Liver Congress (ILC), Paris, France
Farag, M. Et Al. "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B," International Liver Congress (ILC), Paris, France, 2018
Farag, M. Et Al. "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B." International Liver Congress (ILC) , Paris, France, 2018
Farag, M. Et Al. (2018) . "HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B." International Liver Congress (ILC) , Paris, France.
@conferencepaper{conferencepaper, author={M. Farag Et Al. }, title={HBV RNA in serum is an early predictor for sustained immune control following treatment with pegylated interferon alfa in patients with HBeAg negative chronic hepatitis B}, congress name={International Liver Congress (ILC)}, city={Paris}, country={France}, year={2018}}